Processing

Please wait...

Settings

Settings

Goto Application

1. AU2008309940 - HIV preventive vaccine based on HIV specific antibodies

Office
Australia
Application Number 2008309940
Application Date 09.10.2008
Publication Number 2008309940
Publication Date 29.04.2010
Publication Kind B2
IPC
C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
C12N 2740/16134
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16111concerning HIV env
16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
Applicants Technologie Integrale Ltd.
Inventors Filinova, Elena Yu.
Agents Spruson & Ferguson
Priority Data 60/978,536 09.10.2007 US
Title
(EN) HIV preventive vaccine based on HIV specific antibodies
Abstract
(EN) The present invention relates to a method for producing a HIV vaccine, preventing infection with HIV and/or preventing the development of HIV infection in an individual. In particular, the present invention provides formation of HIV specific antibodies capable to recognize and bind to substantially all HIV-isoforms as an immune response in an individual, which bind to existing in a current epidemiologic cohort HIV-subtypes and mutants selected after antiretroviral therapy. The present invention also relates to HIV-1 peptides/polypeptides/proteins selection with reverse panning technique, LC mass spectrometry identification of HIV-1 env peptides/polypeptides/proteins, gp120 and its fragment in particular, production of recombinant HIV-1 env peptides in suitable host with necessary glycosylation - L. tarentolae and using sterically stabilized liposomes (SSL) as an adjuvant-carrier for HIV-specific immune boost composition.
Related patent documents
RU2010116849This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.